Mantle Cell Lymphoma Clinical Trials

A listing of 51 Mantle Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Mantle Cell Lymphoma

1 - 12 of 51

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 51 active clinical trials seeking participants for Mantle Cell Lymphoma research studies. The states with the highest number of trials for Mantle Cell Lymphoma participants are Illinois, New York, California and Washington.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Recruiting

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +118 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Western Regional Medical Center, Llc, Goodyear, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Honor Health Research Institute, Scottsdale, Arizona

University of Arizona Cancer Center, Tucson, Arizona

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California

UCLA Santa Monica Cancer Care, Santa Monica, California

Stanford Medicine, Stanford, California

Uchealth North, Fort Collins, Colorado

Mayo Clinic Jacksonville, Jacksonville, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Tampa General Hospital Cancer Institute, Tampa, Florida

Augusta University, Augusta, Georgia

Southeastern Regional Medical Center, Newnan, Georgia

Midwestern Regional Medical Center, Zion, Illinois

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Norton Cancer Institute Pavilion, Louisville, Kentucky

Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

American Oncology Partners of Maryland Pa, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Nebraska Cancer Specialists, Grand Island, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Summit Medical Group, Florham Park, New Jersey

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Weill Cornell Medical College Newyork Presbyterian Hospital, New York, New York

Columbia University Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

Tennesse Oncology Chattanooga, Chattanooga, Tennessee

Tennessee Oncology, Pllc Nashville, Nashville, Tennessee

Md Anderson Cancer Center, Houston, Texas

Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Concord Repatriation General Hospital, Concord, New South Wales

Calvary Mater Newcastle, Waratah, New South Wales

Princess Alexandra Hospital, Brisbane, Queensland

St Vincents Hospital Melbourne, Fitzroy, Victoria

Peninsula Private Hospital, Frankston, Victoria

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Linear Clinical Research, Nedlands, Western Australia

Perth Blood Institute, West Perth, Western Australia

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Instituto de Pesquisa Em Saude Da Universidade de Caxias Do Sul, Caxias do Sul, Not set

Hospital Erasto Gaertner, Curitiba, Not set

Hospital Ernesto Dornelles, Porto Alegre, Not set

Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Not set

Real E Benemerita Associacao Portuguesa de Sao Paulo, Sao Paulo, Not set

Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, Not set

Hospital Nove de Julho Dasa, Sao Paulo, Not set

Hospital Alemao Oswaldo Cruz, Sao Paulo, Not set

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, Not set

Hospital Santa Rita de Cassia Afecc, Vitoria, Not set

Cross Cancer Institute, Edmonton, Alberta

British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia

Princess Margaret Cancer Centre, Toronto, Ontario

Arthur Je Child Comprehensive Cancer Centre, Calgary, Not set

Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Quebec, Not set

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Hopital Estaing, Clermont Ferrand, Not set

Chu Henri Mondor, Creteil, Not set

Hopital Claude Huriez Chu Lille, Lille, Not set

Centre Leon Berard, Lyon Cedex, Not set

Institut Paoli Calmettes, Marseille, Not set

Chu Montpellier Hopital Saint Eloi, Montpellier Cedex, Not set

Hopital de La Pitie Salpetriere, Paris, Not set

Centre Henri Becquerel, Rouen Cedex, Not set

Arensia Exploratory Medicine Llc, Tbilisi, Not set

Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden, Dresden, Not set

Uniklinik Koln (Aor), Koln, Not set

Universitares Krebszentrum Leipzig, Leipzig, Not set

Universitaetsklinikum Schleswig Holstein Campus Luebeck, Luebeck, Not set

Klinikum Johannes Gutenberg Universitaet Mainz, Mainz, Not set

Klinikum Grosshadern Ludwig Maximilians Universitat Munchen, Munich, Not set

Universitaetsklinikum Ulm, Innere Medizin Iii, Ulm, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Ospedale San Raffaele, Milano, Not set

Istituto Europeo Di Oncologia, Milano, Not set

Niguarda Cancer Center Division of Hematology, Milano, Not set

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Not set

Centroricerche Cliniche Di Verona Srl, Verona, Not set

Aichi Cancer Center Hospital Clinical Oncology, Nagoya, Aichi

Chiba Cancer Center, Chibashi, Chiba

National Cancer Center Hospital East, Kashiwa, Chiba

Cancer Institute Hospital of Jfcr, Kotoku, Tokyo

Yokohama Municipal Citizens Hospital, Yokohamashi, Not set

Inje University Busan Paik Hospital, Busan, Busan Gwang'yeogsi

Pusan National University Hospital, Busan, Busan Gwang'yeogsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Hospital de La Santa Creu I Sant Pau, Barcelona, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Md Anderson Cancer Center Madrid Spain, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Sahlgrenska University Hospital Hematology, Goteborg, Not set

Karolinska Universitetssjukhuset Solna, Stockholm, Not set

Uppsala Akademiska Sjukhus, Uppsala, Not set

Dr Abdurrahman Yurtaslan Research and Training Hospital, Ankara, Not set

Ankara University, Ankara, Not set

Dokuz Eylul University, Izmir, Not set

Erciyes University, Kayseri, Not set

Sakarya Training and Research Hospital, Sakarya, Not set

Ondokuz Mayis University, Samsun, Not set

Edinburgh Cancer Centre, Edinburgh, Not set

Churchill Hospital Oxford University Hospital Nhs Trust, Headington, Not set

St Jamess University Hospital, Leeds, Not set

Freeman Hospital, NewCastle Upon Tyne, Not set

Nottingham University Hospitals Nhs Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

Learn More ›

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma

NCT06742996

Recruiting

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/20/2025

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +139 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Mayo Clinic Phoenix, Phoenix, Arizona

Yale University, Yale Cancer Center, New Haven, Connecticut

Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, Florida

Cleveland Clinic Florida, Weston, Florida

Rush University Medical Center, Chicago, Illinois

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Mission Cancer and Blood, Des Moines, Iowa

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Dana Farber Cancer Institute Longwood Medical Center, Boston, Massachusetts

Mayo Clinic Rochester, Rochester, Minnesota

Hattiesburg Hematology and Oncology Clinic, Hattiesburg, Mississippi

Washington University School of Medicine, Saint Louis, Missouri

The Valley Hospital, Inc, Paramus, New Jersey

Atrium Health Levine Cancer Institute (Lci), Charlotte, North Carolina

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Ohio Health Research Institute, Columbus, Ohio

Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania

McGlinn Cancer Institute, West Reading, Pennsylvania

Tennessee Oncology, Nashville, Tennessee

Md Anderson Cancer Center, Houston, Texas

Texas Oncology Austin Midtown, Round Rock, Texas

University of Virginia, Charlottesville, Virginia

Virgina Cancer Specialists, Gainesville, Virginia

Vcu Massey Cancer Center, Richmond, Virginia

Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver, Washington

Hospital Italiano de Buenos Aires, Buenos Aires, Not set

Hospital Aleman, Caba, Not set

FUNDALEU, Caba, Not set

Hospital Universitario de Cordoba, Cordoba, Not set

Concord Repatriation General Hospital, Concord, New South Wales

Genesiscare North Shore, St Leonards, New South Wales

Westmead Hospital, Westmead, New South Wales

Sunshine Coast Hospital and Health Service, Birtinya, Queensland

Box Hill Hospital, Box Hill, Victoria

Monash Health, Clayton, Victoria

Rockingham Hospital, Cooloongup, Western Australia

Linear Clinical Research, Nedlands, Western Australia

One Clinical Research, Nedlands, Western Australia

Perth Blood Institute, West Perth, Western Australia

Ordensklinikum Linz Gmbh Elisabethinen, Linz, Not set

Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg, Salzburg, Not set

Uk St Poelten, St Poelten, Not set

Medical University Vienna Oncology, Vienna, Not set

Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Not set

Hospital Felicio Rocho, Belo Horizonte, Not set

Universidade de Campinas Centro de Hematologia E Hemoterapia, Campinas, Not set

Hospital Erasto Gaertner, Curitiba, Not set

Instituto Joinvilense de Hematologia E Oncologia, Joinville, Not set

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Not set

Hospital de Clinicas de Porto Alegre, Porto AlegreRS, Not set

Hospital Do Cancer de Pernambuco, Recife, Not set

Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular, Sao Paulo, Not set

Hospital Santa Rita de Cassia Afecc, Vitoria, Not set

Beijing Cancer Hospital, Beijing, Beijing

Beijing Hospital, Beijing, Beijing

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing

Fujian Medical University Union Hospital, Fuzhou, Fujian

Sun Yat Sen University Cancer Center, Guangzhou, Guangdong

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Jiangsu Province Hospital, Nanjing, Jiangsu

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu

Jiangxi Province Cancer Hospital, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Shaanxi Provincial Peoples Hospital, Xian, Shaanxi

Linyi Cancer Hospital, Linyi, Shandong

The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong

Fudan University Shanghai Cancer Center, Shanghai, Shanghai

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan

The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan, Hangzhou, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang

Chu Montpellier Hopital Saint Eloi, Montpellier Cedex, Not set

Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes Cedex, Not set

Chu Hopital Lyon Sud, PierreBenite, Not set

Chu Tours Hopital Bretonneau, Tours, Not set

Klinikum Chemnitz Ggmbh, Chemnitz, Not set

Klinikum Der Johann Wolfgang Goethe Universitat Medizinische Klinik I, Frankfurt am Main, Not set

Universitatsklinikum Halle, Halle, Not set

Universitatsklinikum Hamburg Eppendorf, Hamburg, Not set

Dept of Medicine Iii, University Hospitallmu, Munich, Not set

Stauferklinikum Schwabisch Gmund Kliniken Ostalb, Mutlangen, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Ospedale Vito Fazzi, Asl Lecce, Leece, Not set

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst, Meldola, Not set

Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Not set

Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Not set

Aichi Cancer Center Hospital Clinical Oncology, Nagoya, Aichi

Toyohashi Municipal Hospital, Toyohashi, Aichi

Chiba Cancer Center, Chibashi, Chiba

Matsuyama Red Cross Hospital, Matsuyamashi, Ehime

Ogaki Municipal Hospital, Ogaki, Gifu

Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshimashi, Hiroshima

Kobe City Medical Center General Hospital, Kobe, Hyogo

Kagoshima University Hospital, Kagoshimashi, Kagoshima

Kanagawa Cancer Center, Yokohamashi, Kanagawa

Tohoku University Hospital, Sendaishi, Miyagi

Kurashiki Central Hospital, Kurashikishi, Okayama

Osaka Red Cross Hospital, Osakashi, Osaka

Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama

National Hospital Organization Okayama Medical Center, Okayama, Not set

Osaka Metropolitan University Hospital, Osaka, Not set

Institute of Science Tokyo Hospital, Tokyo, Not set

Yokohama Municipal Citizens Hospital, Yokohamashi, Not set

Pusan National University Hospital, Busan, Busan Gwang'yeogsi

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Yeouido St Marys Hospital, Seoul, Seoul Teugbyeolsi

Christchurch Hospital, Christchurch, Not set

Dunedin Hospital, Dunedin, Not set

North Shore Hospital, Takapuna, Not set

Tauranga Hospital, Tauranga, Not set

Pratia McM Krakow, Krakow, Not set

Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi, Lodz, Not set

Uniwersytecki Szpital Kliniczny Nr W Lublinie, Lublin, Not set

Aidport Sp Z O O, Skorzewo, Not set

Lower Silesian Center of Oncology, Pulmonology and Hematology, Wroclaw, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Ceim Hospital Clinic de Barcelona, Barcelona, Not set

Ico H Duran I Reynals, Barcelona, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

H Puerta de Hierro Majadahonda, Madrid, Not set

Etlik City Hospital, Ankara, Not set

Antalya Memorial Hospital, Antalya Memorial Hospital, Not set

Tr Trakya University Health Research and Application Center (Hospital), Edirne, Not set

Kocaeli Universitesi Tip Fakultesi, Kocaeli, Not set

Birmingham Heartlands Hospital, Birmingham, Not set

The Royal Bournemouth and Christchurch Hospitals Nhs Foundation, Bournemouth, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Churchill Hospital Oxford University Hospital Nhs Trust, Headington, Not set

University College Hospital, London, Not set

Derriford Hospital, Plymouth, Not set

Clatterbridge Cancer Centre, Wirral, Not set

Conditions: Mantle Cell Lymphoma, B Cell Lymphoma

Learn More ›

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491

Recruiting

To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/18/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Mantle Cell Lymphoma

Learn More ›

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029

Recruiting

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/18/2025

Locations: California Research Institute, Los Angeles, California +14 locations

Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence

Learn More ›

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050

Recruiting

This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for c... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

03/17/2025

Locations: City of Hope Medical Center, Duarte, California

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma

Learn More ›

Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

NCT06784167

Recruiting

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: OHSU Knight Cancer Institute, Portland, Oregon

Conditions: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Primary Mediastinal Large B-Cell Lymphoma, Small Lymphocytic Lymphoma

Learn More ›

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients with B-cell Malignancies Undergoing Treatment with Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT06151730

Recruiting

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

Gender:

ALL

Ages:

All

Trial Updated:

03/13/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia

Learn More ›

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

NCT06572618

Recruiting

This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/04/2025

Locations: City of Hope Medical Center, Duarte, California +1 locations

Conditions: Mantle Cell Lymphoma

Learn More ›

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

NCT03523975

Recruiting

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/04/2025

Locations: City of Hope Medical center, Duarte, California +2 locations

Conditions: Mantle Cell Lymphoma

Learn More ›

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects with Relapsed/Refractory Hematological Malignancies

NCT05887167

Recruiting

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

03/03/2025

Locations: Cedars-Sinai Medical Center, Los Angeles, California

Conditions: Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma

Learn More ›

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT05724121

Recruiting

Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart. Objective: To identify and monitor the effects of BTKi on the heart. Eligibility: People aged 18 and older currently receiving or planning to receive BTKi or venetoclax. Design: Participants who h... Read More

Gender:

ALL

Ages:

Between 18 years and 110 years

Trial Updated:

03/01/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death, Cardiac Arrhythmias, Hematologic Malignancies

Learn More ›

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT04223765

Recruiting

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For this study, the anti-kappa light chain antibody has been changed so instead of floating free in the blood, a part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymphoma cells is attached to the T cells. When an antibody is joined to a T cell in this way, it is called a chimeric receptor. The kappa light chain chimeric (combination) receptor-activated T cells are called ATLCAR.κ.28 cells. These cells may be able to destroy lymphoma cancer cells. They do not, however, last very long in the body so their chances of fighting the cancer are unknown. Previous studies have shown that a new gene can be put into T cells to increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying your genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes an antibody called an anti-kappa light chain. This anti-kappa light chain antibody usually floats around in the blood. The antibody can detect and stick to cancer cells called lymphoma cells because they have a substance on the outside of the cells called kappa light chains. The purpose of this study is to determine whether receiving the ATLCAR.κ.28 cells is safe and tolerable and learn more about the side effects and how effective these cells are in fighting lymphoma. Initially, the study doctors will test different doses of the ATLCAR.κ.28, to see which dose is safer for use in lymphoma patients. Once a safe dose is identified, the study team will administer this dose to more patients, to learn about how these cells affect lymphoma cancer cells and identify other side effects they might have on the body. This is the first time ATLCAR.κ.28 cells are given to patients with lymphoma. The Food and Drug Administration (FDA), has not approved giving ATLCAR.κ.28 as treatment for lymphoma. This is the first step in determining whether giving ATLCAR.κ.28 to others with lymphoma in the future will help them. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2025

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma

Learn More ›

1 - 12 of 51